Biology News
BriaCell's Lead Product Candidate's Novel Mechanism of Action Published in a Reputable Immunology Journal - GlobeNewswire (press release)


GlobeNewswire (press release)
BERKELEY, Calif. and VANCOUVER, British Columbia, May 21, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted ...

Cancer cells co-opt pain-sensing 'wasabi receptor' to survive oxidative stress - Science Daily


Science Daily
Tumor cells appear to have co-opted this neural protein channel, which is associated with multiple types of cancer, to protect themselves against oxidative stress," said senior study author Joan Brugge, the Louise Foote Pfeiffer Professor of Cell ...

Jeff Sands named 91st president of American Physiological Society - Emory News Center


Emory News Center
In addition, Sands will work with Edward Morgan, PhD, professor of pharmacology in Emory's Department of Pharmacology and president of the American Society for Pharmacology and Experimental Therapeutics (ASPET), to plan a first-ever APS-ASPET joint ...

Protein Therapeutics Discovery and Development

Fulshear - United States

This conference will explore the therapeutic applications of proteins, the discovery and design of therapeutics, the problems associated with protein based drugs and new tools and strategies in process development.

Related
Evidence of a new type of protein-protein interaction
Russian Federation

Desensitized actomyosin blocks Ca2+-sensitivity of the natural one. Physiological Chemistry and Physics and Medical NMR, 32: 167-179, 2000.

Silence Therapeutics
Germany

Developing RNAi therapeutics using siRNA-based technology called AtuRNAi.

Sirna Therapeutics, Inc.
United States

Develop treatments based on RNAi technology for asthma, diabetes, hepatitis C, macular degeneration and Huntington's Disease. Includes product pipeline, overview of company with research and manufacturing in Boulder, Colorado, headquartered in San Francisco, California.

RNAi Therapeutics: How Likely, How Soon?
United States

Review article from PLoS Biology journal. Describes mechanism of RNA Interference, potential applications towards therapeutics, and current problems associated with delivery.

Cellerant Therapeutics, Inc.
United States

Products based on the regulation of the human haematopoietic (blood-forming) system.

Cytori Therapeutics, Inc.
United States

Developing proprietary, cell-based therapies from adult adipose tissue, targeting cardiovascular disease, orthopedic conditions, gastrointestinal disorders and autologous reconstructive surgery. International contacts with headquarters in San Diego, California.

RegenoCELL Therapeutics, Inc.
United States

Provides information targeted at investors, about stem cell treatments for congestive heart failure and peripheral artery disease.

VistaGen Therapeutics, Inc.
United States

Developing new generation drug candidates, applying in vitro embryonic technologies to disorders of the central nervous system, diabetes and other metabolic syndromes. Profile and contacts in South San Francisco, California.

Collateral Therapeutics
United States

A product-driven cardiovascular gene therapy company, focused on the discovery, development and commercialization of novel and innovative non-surgical gene therapy products.

Introgen Therapeutics, Inc.
United States

Focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases.